Teva - News Flash - Israel
Teva Pharmaceutical Industries reported positive results from Phase III clinical studies for its QNASL nasal spray. The spray is designed to treat seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). The trials tested the efficacy and safety of the spray, as well as the impact on quality of life. The results were reported at the 2012 American Academy of Allergy, Asthma and Immunology (AAAAI) meeting in Orlando, Florida. View and share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Red Algae Can Treat Wounds And Infections
January 26, 2023

Freight Planner Lists on Nasdaq And Raises $80M
January 26, 2023

$6M Investment For “Lettuce Milk” Startup
January 25, 2023

Israel Has World’s Best Value Internet
January 25, 2023
Facebook comments